Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review

被引：141

作者：

Piper-Vallillo, Andrew J. ^{[1
,2
,3
]}

Sequist, Lecia, V ^{[2
,3
]}

Piotrowska, Zofia ^{[2
,3
]}

机构：

[1] Beth Israel Deaconess Med Ctr, Dept Med, Div Med Oncol, Boston, MA 02215 USA

[2] Harvard Med Sch, Boston, MA 02115 USA

[3] Massachusetts Gen Hosp, Dept Med, Div Hematol Oncol, Boston, MA 02114 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 25期

关键词：

TYROSINE KINASE INHIBITORS; ACQUIRED-RESISTANCE; 1ST-LINE ERLOTINIB; BRAIN METASTASES; OPEN-LABEL; MUTATION; THERAPY; COMBINATION; CRIZOTINIB; ADENOCARCINOMA;

D O I：

10.1200/JCO.19.03123

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Since its approval in April 2018, osimertinib has been widely adopted as first-line therapy for patients with advancedEGFR-mutant non -small cell lung cancer (NSCLC). Understanding osimertinib resistance mechanisms and currently available treatment options are essential to selecting optimal second line therapy for patients whose disease progresses during front-line osimertinib. Using data compiled from 6 osimertinib-resistance series, we describe here the heterogeneous profile of EGFR-dependent and independent mechanisms of osimertinib treatment failure. We identifiedMETalterations (7%-24%),EGFRC797X (0%-29%), SCLC transformation (2%-15%), and oncogene fusions (1%-10%) as the most common mechanisms of resistance. This review provides an evidence-based, algorithmic approach to the evaluation and management of post-osimertinib progression as well as a compendium of active, enrolling clinical trials for this population.

引用

页码：2926 / +

页数：13

共 90 条

[41] TATTON: a multi-arm, phase lb trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer [J].

Oxnard, G. R. ;

Yang, J. C. -H. ;

Yu, H. ;

Kim, S. -W. ;

Saka, H. ;

Horn, L. ;

Goto, K. ;

Ohe, Y. ;

Mann, H. ;

Thress, K. S. ;

Frigault, M. M. ;

Vishwanathan, K. ;

Ghiorghiu, D. ;

Ramalingam, S. S. ;

Ahn, M. -J. .

ANNALS OF ONCOLOGY, 2020, 31 (04) :507-516

[42] Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T79OM-Positive Lung Cancer and Acquired Resistance to Osimertinib [J].

Oxnard, Geoffrey R. ;

Hu, Yuebi ;

Mileham, Kathryn F. ;

Husain, Hatim ;

Costa, Daniel B. ;

Tracy, Philip ;

Feeney, Nora ;

Sholl, Lynette M. ;

Dahlberg, Suzanne E. ;

Redig, Amanda J. ;

Kwiatkowski, David J. ;

Rabin, Michael S. ;

Paweletz, Cloud P. ;

Thress, Kenneth S. ;

Janne, Pasi A. .

JAMA ONCOLOGY, 2018, 4 (11) :1527-1534

[43] Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer [J].

Oxnard, Geoffrey R. ;

Thress, Kenneth S. ;

Alden, Ryan S. ;

Lawrance, Rachael ;

Paweletz, Cloud P. ;

Cantarini, Mireille ;

Yang, James Chih-Hsin ;

Barrett, J. Carl ;

Janne, Pasi A. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (28) :3375-+

[44] Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation [J].

Oxnard, Geoffrey R. ;

Arcila, Maria E. ;

Sima, Camelia S. ;

Riely, Gregory J. ;

Chmielecki, Juliann ;

Kris, Mark G. ;

Pao, William ;

Ladanyi, Marc ;

Miller, Vincent A. .

CLINICAL CANCER RESEARCH, 2011, 17 (06) :1616-1622

[45] Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib [J].

Oztan, A. ;

Fischer, S. ;

Schrock, A. B. ;

Erlich, R. L. ;

Lovly, C. M. ;

Stephens, P. J. ;

Ross, J. S. ;

Miller, V. ;

Ali, S. M. ;

Ou, S. -H. I. ;

Raez, L. E. .

LUNG CANCER, 2017, 111 :84-87

[46]

Papadimitrakopoulou VA, 2018, ANN ONCOL, V29, P741

[47] First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer The ASPIRATION Study [J].

Park, Keunchil ;

Yu, Chong-Jen ;

Kim, Sang-We ;

Lin, Meng-Chih ;

Sriuranpong, Virote ;

Tsai, Chun-Ming ;

Lee, Jong-Seok ;

Kang, Jin-Hyoung ;

Chan, K. C. Allen ;

Perez-Moreno, Pablo ;

Button, Peter ;

Ahn, Myung-Ju ;

Mok, Tony .

JAMA ONCOLOGY, 2016, 2 (03) :305-312

[48] Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial [J].

Paz-Ares, Luis ;

Dvorkin, Mikhail ;

Chen, Yuanbin ;

Reinmuth, Niels ;

Hotta, Katsuyuki ;

Trukhin, Dmytro ;

Statsenko, Galina ;

Hochmair, Maximilian J. ;

Ozguroglu, Mustafa ;

Ji, Jun Ho ;

Voitko, Oleksandr ;

Poltoratskiy, Artem ;

Ponce, Santiago ;

Verderame, Francesco ;

Havel, Libor ;

Bondarenko, Igor ;

Kazarnowicz, Andrzej ;

Losonczy, Gyorgy ;

Conev, Nikolay V. ;

Armstrong, Jon ;

Byrne, Natalie ;

Shire, Norah ;

Jiang, Haiyi ;

Goldman, Jonathan W. ;

Batagelj, Emilio ;

Casarini, Ignacio ;

Pastor, Anea Viviana ;

Sena, Susana Noemi ;

Zarba, Juan Jose ;

Burghuber, Otto ;

Hartl, Sylvia ;

Hochmair, Maximilian J. ;

Lamprecht, Bernd ;

Studnicka, Michael ;

Schlittler, Luis Alberto ;

de Oliveira, Fabricio Augusto Martinelli ;

Calabrich, Aknar ;

Girotto, Gustavo Colagiovanni ;

Dos Reis, Peo ;

Gorini, Carlos Fausto Nino ;

De Marchi, Peo Rafael Martins ;

Baldotto, Clarissa Serodio da Rocha ;

Sette, Claudia ;

Zukin, Mauro ;

Conev, Nikolay V. ;

Dudov, Assen ;

Ilieva, Rumyana ;

Koynov, Krassimir ;

Krasteva, Rositsa ;

Tonev, Ivan .

LANCET, 2019, 394 (10212) :1929-1939

[49] SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer [J].

Pennell, Nathan A. ;

Neal, Joel W. ;

Chaft, Jamie E. ;

Azzoli, Christopher G. ;

Jaenne, Pasi A. ;

Govindan, Ramaswamy ;

Evans, Tracey L. ;

Costa, Daniel B. ;

Wakelee, Heather A. ;

Heist, Rebecca S. ;

Shapiro, Marc A. ;

Muzikansky, Alona ;

Murthy, Sudish ;

Lanuti, Michael ;

Rusch, Valerie W. ;

Kris, Mark G. ;

Sequist, Lecia V. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (02) :97-+

[50] ELIOS: A Multicenter, Open-Label, Molecular Profiling Study of Patients with EGFRm and NSCLC Treated with Osimertinib [J].

Piotrowska, Z. ;

Chmielecki, J. ;

Cripps, D. ;

Miranda, M. .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) :S493-S494

← 1 2 3 4 5 6 7 8 9 →